Results

1–10 of 82 results for ranibizumab

Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023
Impact and Outcomes of Anti-VEGF Prior Authorization Requests: Insights From a Large Database Analysis
Saira Khanna, MD
Annual Meeting Talks
2023
Efficacy and Safety of Biosimilar Ranibizumab-nuna and Ranibizumab-eqrn in Clnical Use by a Consortium of Retina Specialists
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2023
Long-Term Efficacy and Safety of the Port Delivery System With Ranibizumab in Patients With nAMD: Results of the Portal 5-year Subgroup Analysis
David J Massop, MD
Annual Meeting Talks
2023
Expert Panel:PDS
Robert A. Mittra, MD, FASRS
Dante Joseph Pieramici, MD
Aleksandra V. Rachitskaya, MD, FASRS
Margaret A. Chang, MD, MS
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2024
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Durability of Combination Therapy of Sozinibercept, an Anti-VEGF-C/D 'Trap' With Ranibizumab in nAMD or Aflibercept in DME
Nathan C. Steinle, MD
Annual Meeting Talks
2024
Subretinal Aflibercept vs Ranibizumab vs Bevacizumab in the Context of PPV: Pneumatic Displacement With Subretinal Air and tPA in Naïve Submacular Hemorrhage Due to nAMD
Matias Iglicki, MD
Annual Meeting Talks
2024
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2022